Statements in which the resource exists.
SubjectPredicateObjectContext
pubmed-article:19185955rdf:typepubmed:Citationlld:pubmed
pubmed-article:19185955lifeskim:mentionsumls-concept:C0596402lld:lifeskim
pubmed-article:19185955lifeskim:mentionsumls-concept:C0032207lld:lifeskim
pubmed-article:19185955lifeskim:mentionsumls-concept:C0444626lld:lifeskim
pubmed-article:19185955lifeskim:mentionsumls-concept:C0220781lld:lifeskim
pubmed-article:19185955lifeskim:mentionsumls-concept:C0023688lld:lifeskim
pubmed-article:19185955lifeskim:mentionsumls-concept:C1704241lld:lifeskim
pubmed-article:19185955lifeskim:mentionsumls-concept:C1883254lld:lifeskim
pubmed-article:19185955lifeskim:mentionsumls-concept:C0043309lld:lifeskim
pubmed-article:19185955lifeskim:mentionsumls-concept:C1533691lld:lifeskim
pubmed-article:19185955lifeskim:mentionsumls-concept:C2603343lld:lifeskim
pubmed-article:19185955lifeskim:mentionsumls-concept:C0205549lld:lifeskim
pubmed-article:19185955lifeskim:mentionsumls-concept:C1705938lld:lifeskim
pubmed-article:19185955lifeskim:mentionsumls-concept:C1527178lld:lifeskim
pubmed-article:19185955pubmed:issue7lld:pubmed
pubmed-article:19185955pubmed:dateCreated2009-5-4lld:pubmed
pubmed-article:19185955pubmed:abstractTextA series of platinum(II) complexes were synthesised based on the enantiomerically pure amino acid proline. Novel synthetic pathways were developed, adapted from standard peptide chemistry, to produce the 2-aminomethylpyrrolidine (pyrr) ligand and its derivatives with differing arrangements of methyl substituents at the exocyclic amine sites. The crystal structure of [PtCl(2)(R-dimepyrr)] (R-dimepyrr=N,N-dimethyl-2(R)-aminomethylpyrrolidine) is reported and the five-membered ligand ring has been shown to be in an envelope conformation. Cytotoxicity studies were carried out on the ovarian cancer A2780 tumour cell line and its cisplatin-resistant variant, A2780cisR. Remarkably good activity was seen for several of the drugs when compared to cisplatin despite the addition of substantial steric bulk to the amine groups, and there was a lack of cross-resistance with cisplatin seen for some compounds.lld:pubmed
pubmed-article:19185955pubmed:languageenglld:pubmed
pubmed-article:19185955pubmed:journalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:19185955pubmed:citationSubsetIMlld:pubmed
pubmed-article:19185955pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:19185955pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:19185955pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:19185955pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:19185955pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:19185955pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:19185955pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:19185955pubmed:statusMEDLINElld:pubmed
pubmed-article:19185955pubmed:monthJullld:pubmed
pubmed-article:19185955pubmed:issn1768-3254lld:pubmed
pubmed-article:19185955pubmed:authorpubmed-author:ZhangMeiMlld:pubmed
pubmed-article:19185955pubmed:authorpubmed-author:BealePhilip...lld:pubmed
pubmed-article:19185955pubmed:authorpubmed-author:HambleyTrevor...lld:pubmed
pubmed-article:19185955pubmed:authorpubmed-author:DiakosConnie...lld:pubmed
pubmed-article:19185955pubmed:authorpubmed-author:FentonRonald...lld:pubmed
pubmed-article:19185955pubmed:issnTypeElectroniclld:pubmed
pubmed-article:19185955pubmed:volume44lld:pubmed
pubmed-article:19185955pubmed:ownerNLMlld:pubmed
pubmed-article:19185955pubmed:authorsCompleteYlld:pubmed
pubmed-article:19185955pubmed:pagination2807-14lld:pubmed
pubmed-article:19185955pubmed:meshHeadingpubmed-meshheading:19185955...lld:pubmed
pubmed-article:19185955pubmed:meshHeadingpubmed-meshheading:19185955...lld:pubmed
pubmed-article:19185955pubmed:meshHeadingpubmed-meshheading:19185955...lld:pubmed
pubmed-article:19185955pubmed:meshHeadingpubmed-meshheading:19185955...lld:pubmed
pubmed-article:19185955pubmed:meshHeadingpubmed-meshheading:19185955...lld:pubmed
pubmed-article:19185955pubmed:meshHeadingpubmed-meshheading:19185955...lld:pubmed
pubmed-article:19185955pubmed:meshHeadingpubmed-meshheading:19185955...lld:pubmed
pubmed-article:19185955pubmed:meshHeadingpubmed-meshheading:19185955...lld:pubmed
pubmed-article:19185955pubmed:meshHeadingpubmed-meshheading:19185955...lld:pubmed
pubmed-article:19185955pubmed:meshHeadingpubmed-meshheading:19185955...lld:pubmed
pubmed-article:19185955pubmed:meshHeadingpubmed-meshheading:19185955...lld:pubmed
pubmed-article:19185955pubmed:meshHeadingpubmed-meshheading:19185955...lld:pubmed
pubmed-article:19185955pubmed:year2009lld:pubmed
pubmed-article:19185955pubmed:articleTitleSynthesis, characterisation and in vitro cytotoxicity studies of a series of chiral platinum(II) complexes based on the 2-aminomethylpyrrolidine ligand: X-ray crystal structure of [PtCl2(R-dimepyrr)] (R-dimepyrr=N-dimethyl-2(R)-aminomethylpyrrolidine).lld:pubmed
pubmed-article:19185955pubmed:affiliationSchool of Chemistry, The University of Sydney, Sydney, NSW, Australia.lld:pubmed
pubmed-article:19185955pubmed:publicationTypeJournal Articlelld:pubmed
pubmed-article:19185955pubmed:publicationTypeResearch Support, Non-U.S. Gov'tlld:pubmed